Ameritas Investment Partners, Inc. - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 194 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2018. The put-call ratio across all filers is 1.35 and the average weighting 0.3%.

Quarter-by-quarter ownership
Ameritas Investment Partners, Inc. ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$75,384
+197.6%
4,066
+77.6%
0.00%
+200.0%
Q2 2023$25,327
-17.6%
2,2900.0%0.00%0.0%
Q1 2023$30,755
-15.6%
2,2900.0%0.00%0.0%
Q4 2022$36,434
+17.5%
2,2900.0%0.00%0.0%
Q3 2022$31,0000.0%2,2900.0%0.00%0.0%
Q2 2022$31,000
-16.2%
2,2900.0%0.00%0.0%
Q1 2022$37,0000.0%2,2900.0%0.00%0.0%
Q4 2021$37,000
+8.8%
2,2900.0%0.00%0.0%
Q3 2021$34,000
-26.1%
2,2900.0%0.00%
-50.0%
Q2 2021$46,000
-13.2%
2,2900.0%0.00%0.0%
Q1 2021$53,000
-7.0%
2,2900.0%0.00%
-33.3%
Q4 2020$57,000
-40.0%
2,2900.0%0.00%
-25.0%
Q3 2020$95,000
-13.6%
2,2900.0%0.00%
-20.0%
Q2 2020$110,000
-20.3%
2,290
+4.4%
0.01%
-37.5%
Q1 2020$138,000
-49.3%
2,1930.0%0.01%
-33.3%
Q4 2019$272,000
+94.3%
2,193
+3.8%
0.01%
+100.0%
Q3 2019$140,000
-16.7%
2,1120.0%0.01%
-25.0%
Q2 2019$168,000
-16.8%
2,112
+16.8%
0.01%
-11.1%
Q1 2019$202,000
+11.0%
1,8080.0%0.01%
-10.0%
Q4 2018$182,000
-20.2%
1,8080.0%0.01%
-9.1%
Q3 2018$228,000
+50.0%
1,8080.0%0.01%
+57.1%
Q2 2018$152,000
-25.1%
1,808
+193.5%
0.01%
-56.2%
Q1 2014$203,0006160.02%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2018
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$14,787,0002.73%
DeepCurrents Investment Group LLC 416,800$9,620,0000.33%
DUALITY ADVISERS, LP 105,668$2,439,0000.21%
EULAV Asset Management 335,000$7,732,0000.21%
Virtus ETF Advisers LLC 19,375$447,0000.19%
Hennion & Walsh Asset Management, Inc. 135,214$3,121,0000.19%
PDT Partners, LLC 110,592$2,552,0000.18%
KETTLE HILL CAPITAL MANAGEMENT, LLC 70,256$1,622,0000.16%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$3,896,0000.12%
WOODWARD DIVERSIFIED CAPITAL, LLC 8,939$206,0000.12%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders